p53 is most well-known for its role in tumor suppression, however emerging evidence supports that dysregulated p53 activity may also contribute to various aspects of the earliest stages of Alzheimer’s disease (AD) development. Paul Kinnon, CEO, Diadem SpA, Brescia, Italy, provides an overview of the role of p53 and its isoforms in the pathogenesis of AD. Previous research has demonstrated that amyloid and early precursors of AD such as oxidative stress are involved in the bidirectional regulation of p53. Furthermore, when the unfolded conformational variant of p53 (U-p53AZ) is created, this can impact tau and amyloid levels. Therefore, p53 seems to have a substantial role within AD pathogenesis, yet the full extent of its action remains unclear. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
